FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944257973> ?p ?o ?g. }

• W2944257973 abstract "Background: Metastatic breast cancer (MBC) is incurable. Although first-line endocrine therapy is preferred to hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) MBC, combination chemotherapy should be reserved as the initial treatment for patients with rapid clinical progression, life-threatening visceral metastases, and need for rapidly symptom control. Either prolonged chemotherapy or endocrine therapy may be used as maintenance after disease control. However, which maintenance strategy is superior in terms of delaying disease progression as well as maintaining quality of life (QOL) remains uncertain. This phase III trial aims to compare the efficacy and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in HR+/HER2- MBC. Trial Design: FAMILY is a multicenter, randomized, open-label phase III trial for HR+ and HER2- MBC. Eligible participants are randomized (1:1) to receive capecitabine (2000mg/m2 twice daily x 14 days followed by 7 days off) or fulvestrant (500mg Days 0, 14, 28, then every 28 days) until disease progression, unacceptable toxicity, or patient refusal. Stratification factor for randomization is sensitivity to adjuvant hormonal therapy (disease-free interval ≤24 months vs. >24 months). Eligibility Criteria: Eligible patients must have HR+ (ER and/or PR>1%, by IHC) and HER2- MBC; achieved a complete or partial response or stable disease (investigator assessed) after 4-8 cycles of first-line combination chemotherapy. Patients with central nervous system metastasis and/or prior use of endocrine therapy for advanced breast cancer are excluded. Specific Aims: The primary endpoint is progression free survival (PFS). Secondary endpoints include overall survival, overall response rate, disease control rate, safety and QOL. A prospective translational research is also planned to assess the correlations between biomarkers and response. Statistical Design: The planned sample size of 256 patients provides approximately 80% of power to detect a 6 months difference of PFS using a log-rank test with two-sided alpha of 0.05. Target Accrual: Recruitment is ongoing. Up to 256 evaluable subjects will be enrolled within 24 months. (ChiCTR-IIR-17014036). Citation Format: Yao H, Wu W, Ding L, Yu Y, Wang Y, Zeng Y, Zhao J, Li Q. FAMILY: A randomized, multicenter, open-label, phase III trial of fulvestrant versus capecitabine as maintenance therapy after first-line combination chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-05-01." @default.
• W2944257973 created "2019-05-16" @default.
• W2944257973 creator A5006285681 @default.
• W2944257973 creator A5011591031 @default.
• W2944257973 creator A5017359407 @default.
• W2944257973 creator A5037473059 @default.
• W2944257973 creator A5055540048 @default.
• W2944257973 creator A5059896441 @default.
• W2944257973 creator A5062143037 @default.
• W2944257973 creator A5066703129 @default.
• W2944257973 date "2019-02-15" @default.
• W2944257973 modified "2023-09-25" @default.
• W2944257973 title "Abstract OT2-05-01: FAMILY: A randomized, multicenter, open-label, phase III trial of fulvestrant versus capecitabine as maintenance therapy after first-line combination chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer" @default.
• W2944257973 doi "https://doi.org/10.1158/1538-7445.sabcs18-ot2-05-01" @default.
• W2944257973 hasPublicationYear "2019" @default.
• W2944257973 type Work @default.
• W2944257973 sameAs 2944257973 @default.
• W2944257973 citedByCount "0" @default.
• W2944257973 crossrefType "proceedings-article" @default.
• W2944257973 hasAuthorship W2944257973A5006285681 @default.
• W2944257973 hasAuthorship W2944257973A5011591031 @default.
• W2944257973 hasAuthorship W2944257973A5017359407 @default.
• W2944257973 hasAuthorship W2944257973A5037473059 @default.
• W2944257973 hasAuthorship W2944257973A5055540048 @default.
• W2944257973 hasAuthorship W2944257973A5059896441 @default.
• W2944257973 hasAuthorship W2944257973A5062143037 @default.
• W2944257973 hasAuthorship W2944257973A5066703129 @default.
• W2944257973 hasConcept C121608353 @default.
• W2944257973 hasConcept C126322002 @default.
• W2944257973 hasConcept C143998085 @default.
• W2944257973 hasConcept C168563851 @default.
• W2944257973 hasConcept C203092338 @default.
• W2944257973 hasConcept C2775930923 @default.
• W2944257973 hasConcept C2776694085 @default.
• W2944257973 hasConcept C2777176818 @default.
• W2944257973 hasConcept C2777909004 @default.
• W2944257973 hasConcept C2778283404 @default.
• W2944257973 hasConcept C2780482068 @default.
• W2944257973 hasConcept C526805850 @default.
• W2944257973 hasConcept C530470458 @default.
• W2944257973 hasConcept C71924100 @default.
• W2944257973 hasConceptScore W2944257973C121608353 @default.
• W2944257973 hasConceptScore W2944257973C126322002 @default.
• W2944257973 hasConceptScore W2944257973C143998085 @default.
• W2944257973 hasConceptScore W2944257973C168563851 @default.
• W2944257973 hasConceptScore W2944257973C203092338 @default.
• W2944257973 hasConceptScore W2944257973C2775930923 @default.
• W2944257973 hasConceptScore W2944257973C2776694085 @default.
• W2944257973 hasConceptScore W2944257973C2777176818 @default.
• W2944257973 hasConceptScore W2944257973C2777909004 @default.
• W2944257973 hasConceptScore W2944257973C2778283404 @default.
• W2944257973 hasConceptScore W2944257973C2780482068 @default.
• W2944257973 hasConceptScore W2944257973C526805850 @default.
• W2944257973 hasConceptScore W2944257973C530470458 @default.
• W2944257973 hasConceptScore W2944257973C71924100 @default.
• W2944257973 hasLocation W29442579731 @default.
• W2944257973 hasOpenAccess W2944257973 @default.
• W2944257973 hasPrimaryLocation W29442579731 @default.
• W2944257973 hasRelatedWork W2127296490 @default.
• W2944257973 hasRelatedWork W2247216439 @default.
• W2944257973 hasRelatedWork W2296942186 @default.
• W2944257973 hasRelatedWork W2399066128 @default.
• W2944257973 hasRelatedWork W2615274570 @default.
• W2944257973 hasRelatedWork W2944257973 @default.
• W2944257973 hasRelatedWork W3009080976 @default.
• W2944257973 hasRelatedWork W3109378361 @default.
• W2944257973 hasRelatedWork W3155084518 @default.
• W2944257973 hasRelatedWork W4255669842 @default.
• W2944257973 isParatext "false" @default.
• W2944257973 isRetracted "false" @default.
• W2944257973 magId "2944257973" @default.
• W2944257973 workType "article" @default.